Significant response to pembrolizumab plus lenvatinib in Epstein-Barr-virus-associated intrahepatic cholangiocarcinoma: a case report

CONCLUSIONS: As far as we know, this is the first case report about the application of Pembrolizumab with lenvatinib for EBVaiCCA patients. This case indicates that the combination of immunotherapy and antiangiogenic therapy provides a glimmer of hope for advanced EBVaiCCA patients.PMID:38650446 | DOI:10.1080/15384047.2024.2338644

Source: Cancer Biology and Therapy - April 23, 2024 Category: Cancer & Oncology Authors: Lisha Li Dandan Yu Jinru Yang Fangyuan Zhang Dejun Zhang Zhenyu Lin Menglan Zhai Jing Wang Tao Zhang Lei Zhao Source Type: research